cabazitaxel / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

41 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cabazitaxel / Generic mfg.
2012-000996-17: Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life. Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life.

Ongoing
2
25
Europe
Concentrate for solution for infusion, JEVTANA*EV 1FL 60MG 1,5ML+1FL
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA, UNIVERSITA LA SAPIENZA - POLICLINICO UMBERTO I
Subjects affected by metastatic castration refractory prostate cancer progressed or intolerant to a previous docetaxel-based chemotherapy. Soggetti adulti affetti da carcinoma prostatico metastatico resistente alla castrazione e che abbiano ricevuto o siano intolleranti ad una precedente terapia a base di taxani., Subjects affected by metastatic castration refractory prostate cancer progressed or intolerant to a previous docetaxel-based chemotherapy. Soggetti adulti affetti da carcinoma prostatico metastatico resistente alla castrazione e che abbiano ricevuto o siano intolleranti ad una precedente terapia a base di taxani, Diseases [C] - Cancer [C04]
 
 
2011-004712-32: A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

Not yet recruiting
2
31
Europe
CABAZITAXEL, Concentrate and solvent for solution for infusion, JEVTANA
UNICANCER, Sanofi Aventis
Recurrent or metastatic head and neck cancer, Diseases [C] - Cancer [C04]
 
 
2014-001647-20: Weekly cabazitaxel chemotherapy in elderly patients with advanced prostate cancer resistant to previous docetaxel treatment Terapia con cabazitaxel settimanale nei pazienti anziani con cancro della prostata metastatico in progressione dopo trattamento con docetaxel

Ongoing
2
62
Europe
Concentrate and solvent for concentrate for solution for infusion, Jevtana
GIOGer (Gruppo Italiano di Oncologia Geriatrica), Sanofi-Aventis
Castration resistant metastatic prostate cancer progressing after docetaxel based treatment Cancro della prostata in fase metastatica e resistente alla castrazione in progressione dopo terapia con docetaxel, Advanced prostate cancer resistant to previous chemotherapy with docetaxel Cancro della prostata in fase metastatica e resistente alla castrazione in progressione dopo terapia con docetaxel, Diseases [C] - Cancer [C04]
 
 
2011-003346-40: Study to assess the efficacy of budesonide in preventing diarrhea caused by treatment with cabazitaxel (CABARESC)

Ongoing
2
250
Europe
Jevtana, Budesonide, Jevtana, Budesonide, Jevtana, Budesonide
Erasmus MC-Daniël den Hoed, Erasmus MC
metastatic prostate cancer
 
 
2012-003835-40: CANTATA: Chemotherapy comparison in relapsing Prostate Cancer that has spread

Ongoing
2
138
Europe
Jevtana (cabazitaxel), docetaxel, Jevtana 60mg concentrate and solvent for solution for infusion, Docetaxel, Jevtana 60mg concentrate and solvent for solution for infusion, Docetaxel
University of Birmingham, Aventis Pharma Limited (trading as Sanofi), Cancer Research UK
Metastatic Castrate Refractory Prostate Cancer
 
 
2012-004412-55: Cabazitaxel in relapsed high-risk HOrmone-SEnsitiveprostate cancer patients. A multicentric Randomized phase II study.C.HO.SE. Trial

Ongoing
2
140
Europe
CABAZITAXEL, JEVTANA, JEVTANA
AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO, sanofi aventis
Relapsed high-risk hormone-sensitiveprostate cancer
 
 
2013-005504-34: Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)

Ongoing
2
10
Europe
Jevtana®, Jevtana®, Jevtana®
CESAR Central European Society for Anticancer Drug Research - EWIV, Sanofi-Aventis
Stage II with advanced Castration-Resistant Prostate Cancer (CRPC)
 
 
2012-000542-35: Study assessing if a chemotherapy drug called Cabazitaxel is effective in Patients with certain type of breast cancer (HER2 negative) that has spread to brain that is un treatable.

Ongoing
2
62
Europe
Cabazitaxel (Jevtana), Jevtana, Jevtana
The Clatterbridge Cancer Centre NHS Foundation Trust, Sanofi Aventis
Her-2 negative breast cancer with brain metastases
 
 
2015-004937-29: Cabazitaxel response prediction by FCH-PET.

Ongoing
2
30
Europe
[18F]-Fluorocholine, Radiopharmaceutical precursor
VU University Medical Center, Sanofi-Aventis The Netherlands, Cyclotron BV
Metastatic castration-resistant prostate cancer., Metastatic hormone-insensitive prostate cancer., Diseases [C] - Cancer [C04]
 
 
2016-004963-38: Optimal patients with Metastasized Hormone Resistant Prostate Cancer Previously Treated with Docetaxel Optimale behandeling voor patienten met een uitgezaaide hormoonongevoelige prostaatkanker die eerder zijn behandeld met docetaxel.

Ongoing
2
152
Europe
Cabazitaxel/ Jevtana, Xtandi (enzalutamide), Zytiga (abiraterone acetate), XRP6258, Concentrate and solvent for concentrate for solution for infusion, Capsule, soft, Tablet, Jevtana (cabazitaxel), Xtandi (enzalutamide) 40mg soft capsules, Zytiga
Netherlands Cancer Institute, Sanofi Genzyme
Metastasized Castration Resistant Prostate Cancer Gemetastaseerd Castratieresistent Prostaat carcinoom, Prostate cancer Prostaatkanker, Diseases [C] - Cancer [C04]
 
 
Bristol Bladder, NCT01616875 / 2011-004090-82: Trial

Active, not recruiting
2
28
Europe
Cabazitaxel + Cisplatin chemotherapy, Jevtana
University Hospitals Bristol and Weston NHS Foundation Trust, Sanofi
Infiltrating Bladder Urothelial Carcinoma
11/17
01/23
2017-001591-35: Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Studio multicentrico, prospettico, non randomizzato, di fase II volto a valutare l’attività di Cabazitaxel in pazienti affetti da carcinoma corticosurrenale avanzato in progressione dopo precedenti linee di chemioterapia citotossica

Ongoing
2
25
Europe
JEVTANA, [cabazitaxel], Solution for infusion, JEVTANA - 60MG-CONCENT. E SOLV.PER SOLUZ. PER INFUSIONE-USO ENDOVENOSO -CONCENT.:FLACONC.(VETRO)SOLV.: FLACONC.(VETRO)-CONCENT.:1.5ML SOLV.:4.5ML-1FLAC.+1FLAC.
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, AIRC, SANOFI -fornitura gratuita farmaco
Histologically confirmed diagnosis of ACCLocally advanced or metastatic disease not amenable to radical surgery resection Diagnosi istologica di carcinona cortico-surrenale (ACC) Malattia localmente avanzata o metastatica non suscettibile di resezione chirurgica radicale, diagnosis of ACC carcinona cortico-surrenale, Diseases [C] - Cancer [C04]
 
 
2016-001253-41: Impact of cabazitaxel on metastatic bone disease in prostate cancer Impatto di cabazitaxel sulle metastasi ossee in pazienti affetti da cancro della prostata

Ongoing
2
107
Europe
CABAZITAXEL, [IMP1], Powder for solution for infusion, JEVTANA - 60MG-CONCENT. E SOLV.PER SOLUZ. PER INFUSIONE-USO ENDOVENOSO -CONCENT.:FLACONC.(VETRO)SOLV.: FLACONC.(VETRO)-CONCENT.:1.5ML SOLV.:4.5ML-1FLAC.+1FLAC.
GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE, Sanofi S.p.a
1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen. Adenocarcinoma prostatico confermato istologicamente o citologicamente resistente alla ormonoterapia e trattato precedentemente con una terapia contenente docetaxel., Prostate cancer that is resistant to hormone therapy and previously treated with a docetaxel containing regimen. Tumore della prostata non rispondente a ormonoterapia e trattato precedentemente con una terapia contenente docetaxel, Diseases [C] - Cancer [C04]
 
 
ACTRN12617001590358: TheraP: A randomised phase 2 trial of 177-Lutetium-Prostate Specific Membrane Antigen-617 (177Lu-PSMA617) theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer (ANZUP1603)

Active, not recruiting
2
200
 
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Prostate Cancer Foundation Australia, Endocyte, Australian Nuclear Science and Technology Organisation (ANSTO)
Prostate cancer
 
 
2020-000823-38: Study on the interaction between cabazitaxel and darolutamide in patients with metastatic prostate cancer Studie naar de wisselwerking tussen cabazitaxel en darolutamide bij patiënten met uitgezaaide prostaatkanker

Not yet recruiting
2
17
Europe
Tablet, Infusion, darolutamide, Cabazitaxel
Erasmus MC Cancer Institute, Erasmus MC Cancer Institute
metastatic castration-resistant prostate cancer Gemetastaseerde castratie-resistente prostaatkanker, Prostate cancer spread to other parts of the body Uitgezaaide prostaatkanker, Diseases [C] - Cancer [C04]
 
 
CABA-V7, NCT03050866: Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

Active, not recruiting
2
140
Europe
Cabazitaxel, Jevtana, Antihistamine, Corticosteroid, H2 antagonist, histamine H2 receptors blockers, Antiemetic
Erasmus Medical Center, Sanofi
Circulating Tumor Cell, Metastatic Prostate Cancer
01/22
08/22
CheckMate 650, NCT02985957 / 2016-001928-54: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Checkmark From CheckMate-650 trial in combination with Yervoy for 2L mCRPC
Sep 2020 - Sep 2020: From CheckMate-650 trial in combination with Yervoy for 2L mCRPC
Checkmark In combination with Yervoy (CheckMate 650 trial)
Mar 2019 - Mar 2019: In combination with Yervoy (CheckMate 650 trial)
Active, not recruiting
2
351
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Cabazitaxel, Prednisone
Bristol-Myers Squibb
Prostate Cancer
04/22
01/25
2019-004817-15: A prospective, biomarker-based, clinical trial in patients with metastatic castration resistant prostate cancer

Not yet recruiting
2
150
Europe
cabazitaxel, Docetaxel Zentiva, Xtandi, Concentrate and solvent for solution for infusion, Tablet, Capsule, Cabazitaxel Jevtana, Docetaxel zentiva, Zytiga, Xtandi
GZA vzw, Kom op tegen Kanker
Metastatic castration resistant prostate cancer, Metastatic castration resistant prostate cancer, Diseases [C] - Cancer [C04]
 
 
2020-000209-10: Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPC

Not yet recruiting
2
160
Europe
Durvalumab, Cabazitaxel, AZD4635, MEDI4736, Capsule, hard, Concentrate for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Jevtana
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Progressive Metastatic Castrate-Resistant Prostate Cancer, Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
NCT02478502 / 2012-004418-32: Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Terminated
2
14
Europe
cabazitaxel, Jevtana
University Hospital, Akershus, Sanofi
Testicular Cancer
12/22
12/22
2022-003792-41: Chemotherapy with or without darolutamide in men with metastatic prostate cancer.

Not yet recruiting
2
245
Europe
Nubeqa, Tablet, Nubeqa/Darolutamide
Erasmus MC, Bayer
metastatic castration-resistant prostate cancer, Prostate cancer spread to other parts of the body, Diseases [C] - Cancer [C04]
 
 
NCT05005728: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
85
US
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Xencor, Inc.
Metastatic Castration-Resistant Prostate Cancer
03/25
09/25
NCT03556904: FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Completed
2
13
US
Ablative Radiation Therapy, Hormone therapy or chemotherapy, enzalutamide, abiraterone, docetaxel, cabazitaxel
University of Michigan Rogel Cancer Center
Prostate Cancer
07/23
07/23
NCT02218606: Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Completed
2
80
US
Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, prednisone 5 mg po BID
Memorial Sloan Kettering Cancer Center, Sanofi, Thomas Jefferson University, Weill Medical College of Cornell University
Prostate Cancer
10/23
10/23
NCI-2018-01071, NCT03263650: Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Active, not recruiting
2
119
US
Cabazitaxel, Jevtana, Carboplatin, Paraplatin, Prednisone 5Mg, Olaparib, Olaparib Pill
M.D. Anderson Cancer Center, AstraZeneca, Merck Sharp & Dohme LLC
Prostate Cancer Aggressiveness, Prostate Carcinoma
06/24
06/24
CHAARTED2, NCT03419234: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Active, not recruiting
2
223
US
Abiraterone Acetate, CB7630, Zytiga, Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Laboratory Biomarker Analysis, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
06/24
04/26
CABPOSTAAT, NCT03764540: Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

Active, not recruiting
2
214
Canada
Cabazitaxel plus prednisone, Experimental, Docetaxel plus prednisone, Active Comparator
Centre hospitalier de l'Université de Montréal (CHUM), Genzyme, a Sanofi Company
Metastatic Prostate Cancer
07/24
09/24
CHAMP, NCT04709276: A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Recruiting
2
43
US
Nivolumab, BMS-936558, MDX1106, ONO-4538, Ipilimumab, BMS-734016, MDX010, MDX-CTLA4, Carboplatin, Cabazitaxel, JEVTANA
Andrew J. Armstrong, MD, Bristol-Myers Squibb
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
12/24
06/27
CASCARA, NCT03934840: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Active, not recruiting
2
22
US
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Masonic Cancer Center, University of Minnesota
Prostate Cancer
06/23
05/25
DynaMO, NCT02703623: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
196
US
Abiraterone Acetate, CB7630, Zytiga, Apalutamide, ARN 509, ARN-509, ARN509, JNJ 56021927, JNJ-56021927, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
03/26
03/26
NCT03048942: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Recruiting
2
160
Europe
Cabazitaxel, Jevtana, Paclitaxel
University Hospitals Bristol and Weston NHS Foundation Trust
HER2 Negative Metastatic Breast Cancer
08/25
08/25
CHROME, NCT04622761: Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

Not yet recruiting
2
120
NA
Cabazitaxel, jevtana, XRP6258, RPR116258A
The Clatterbridge Cancer Centre NHS Foundation Trust, University of Liverpool
Prostate Cancer
11/25
05/26
NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
PEAPOD_FOS, NCT05563558: Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer

Recruiting
2
42
Europe
Pembrolizumab, Carboplatin, Cabazitaxel
Fundacion Oncosur
Prostate Cancer Metastatic
11/26
11/26
DAROTAXEL, NCT05762536: Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

Recruiting
2
245
Europe
Darolutamide, Docetaxel or cabazitaxel
Erasmus Medical Center
Metastatic Castration-resistant Prostate Cancer
05/27
05/28
2006-003085-34: A Dose-escalating, Multicenter, Single arm, Open-label Study of XRP6258 in combination with capecitabine (Xeloda®), in patients with metastatic breast cancer with disease progressing after anthracycline and taxane therapy

Ongoing
1/2
50
Europe
XRP6258, Concentrate for solution for infusion, Film-coated tablet, Xeloda
sanofi-aventis recherche & developpement
Metastatic Breast Cancer
 
 
c15-148, NCT02522715: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
37
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Enzalutamide, ASP9785, MDV3100, Xtandi, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
OHSU Knight Cancer Institute, Oregon Health and Science University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
10/19
07/24
NCT02202772: Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Active, not recruiting
1/2
51
US
Cabazitaxel, Jevtana, Gemcitabine, Gemzar, Cisplatin, Platinol, Platinol-AQ
Guarionex J. Decastro, Sanofi
Urothelial Carcinoma of the Urinary Bladder
04/26
04/28
MK-5684-01A, NCT06353386: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Recruiting
1/2
220
RoW
Opevesostat, MK-5684, Olaparib, LYNPARZA®, Docetaxel, TAXOTERE®, Cabazitaxel, JEVTANA®, Fludrocortisone acetate, Dexamethasone, Prednisone
Merck Sharp & Dohme LLC, Orion Corporation, Orion Pharma
Prostatic Neoplasms, Castration-Resistant
03/28
03/28
NCT06085729: Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Recruiting
1/2
30
US
ADI-PEG 20, Cabazitaxel, Jevtana®, Carboplatin, Paraplatin®
M.D. Anderson Cancer Center
Prostate Cancer
12/25
12/27
LuCAB, NCT05340374: Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Recruiting
1/2
44
RoW
Cabazitaxel, 177Lu-PSMA-617
Peter MacCallum Cancer Centre, Australia
Metastatic Castration-resistant Prostate Cancer, mCRPC
06/26
12/26

Download Options